BARDA DRIVe partners with US Biologic, Inc. in the development of an oral vaccine for pandemic influenza
The U.S. DHHS Biomedical Advanced Research and Development Authority (BARDA) Division of Research Innovation and Ventures (DRIVe) is partnering with US Biologic Inc. to advance the development of an oral vaccine for the influenza virus. This partnership aligns with the goals of BARDA DRIVe’s Beyond the Needle program: to make vaccines and therapeutics easier to administer and more widely available, without the need for needles, syringes, vials, and cold-chain distribution burdens.